AI assistant
Spyre Therapeutics, Inc. — Director's Dealing 2017
Dec 6, 2017
32226_dirs_2017-12-05_a6020735-a69d-4726-b9fe-144e59e771f9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2017-12-01
Reporting Person: York Charles N II (Chief Financial Officer and VP)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-08-15 | Common Stock | P | 2000 | $3.987 | Acquired | 10828 | Direct |
| 2017-02-15 | Common Stock | P | 2000 | $4.284 | Acquired | 12828 | Direct |
| 2017-08-15 | Common Stock | P | 1959 | $2.516 | Acquired | 14787 | Direct |
| 2017-12-01 | Common Stock | P | 6500 | $4.5931 | Acquired | 21287 | Direct |
| 2017-12-04 | Common Stock | P | 3259 | $4.9699 | Acquired | 24546 | Direct |
| 2017-12-05 | Common Stock | P | 10241 | $4.7554 | Acquired | 34787 | Direct |
Footnotes
F1: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.48 to $4.65 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.
F3: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.84 to $5.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.
F4: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.69 to $5.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.